15 December 2014
IntegraGen licenses liver cancer molecular signatures
IntegraGen has announced that it has entered into an agreement providing the company with the worldwide licensing rights for two hepatocellular carcinoma molecular signatures which have potential clinical utility for monitoring patients with liver cancer.
